Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen

the French Genito-Urinary Tumor Group (GETUG)

doi:10.1016/j.ejca.2018.09.002

Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen

the French Genito-Urinary Tumor Group (GETUG)

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

19 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	236-238
Nombre de pages	3
journal	European Journal of Cancer
Volume	104
Les DOIs	https://doi.org/10.1016/j.ejca.2018.09.002
état	Publié - 1 nov. 2018

Accès au document

10.1016/j.ejca.2018.09.002

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{6f36bf2967ce44a886c2b36c07434d17,

title = "Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen",

author = "{the French Genito-Urinary Tumor Group (GETUG)} and Gwena{\"e}lle Gravis and Emilien Billon and Capucine Baldini and Christophe Massard and Werner Hilgers and Remy Delva and Jochen Walz and Geraldine Pignot and Stanislas Rybikowski and Slimane Dermeche and Jeanne Thomassin and Serge Brunelle and Pernelle Lavaud and Yohann Loriot",

note = "Funding Information: Gwena{\"e}lle Gravis has declared travelling expenses from BMS and Roche. Werner Hilgers has received honoraria for the advisory board from AstraZeneca, BMS and Roche. Yohann Loriot has reported research grant from Sanofi, Janssen and for attending advisory boards from Janssen, Astellas, Seattle Genetics, MSD, AZ, Pfizer, Roche, and BMS. Pernelle Lavaud has declared travelling expenses from AstraZeneca and Pfizer. Christophe Massard has received personal fees from Amgen, Astellas, AstraZeneca, Bayer, Celgene, Genentech, Ipsen, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi and Orion. Jochen Walz received honoraria from Takeda, Ipsen, Astellas and Janssen. The other authors have reported no potential conflicts of interest.",

year = "2018",

month = nov,

day = "1",

doi = "10.1016/j.ejca.2018.09.002",

language = "English",

volume = "104",

pages = "236--238",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

TY - JOUR

T1 - Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen

AU - the French Genito-Urinary Tumor Group (GETUG)

AU - Gravis, Gwenaëlle

AU - Billon, Emilien

AU - Baldini, Capucine

AU - Massard, Christophe

AU - Hilgers, Werner

AU - Delva, Remy

AU - Walz, Jochen

AU - Pignot, Geraldine

AU - Rybikowski, Stanislas

AU - Dermeche, Slimane

AU - Thomassin, Jeanne

AU - Brunelle, Serge

AU - Lavaud, Pernelle

AU - Loriot, Yohann

N1 - Funding Information: Gwenaëlle Gravis has declared travelling expenses from BMS and Roche. Werner Hilgers has received honoraria for the advisory board from AstraZeneca, BMS and Roche. Yohann Loriot has reported research grant from Sanofi, Janssen and for attending advisory boards from Janssen, Astellas, Seattle Genetics, MSD, AZ, Pfizer, Roche, and BMS. Pernelle Lavaud has declared travelling expenses from AstraZeneca and Pfizer. Christophe Massard has received personal fees from Amgen, Astellas, AstraZeneca, Bayer, Celgene, Genentech, Ipsen, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi and Orion. Jochen Walz received honoraria from Takeda, Ipsen, Astellas and Janssen. The other authors have reported no potential conflicts of interest.

PY - 2018/11/1

Y1 - 2018/11/1

UR - http://www.scopus.com/inward/record.url?scp=85056595101&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.09.002

DO - 10.1016/j.ejca.2018.09.002

M3 - Letter

C2 - 30316610

AN - SCOPUS:85056595101

SN - 0959-8049

VL - 104

SP - 236

EP - 238

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -